<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0186-4866</journal-id>
<journal-title><![CDATA[Medicina interna de México]]></journal-title>
<abbrev-journal-title><![CDATA[Med. interna Méx.]]></abbrev-journal-title>
<issn>0186-4866</issn>
<publisher>
<publisher-name><![CDATA[Edición y Farmacia S.A. de C.V.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0186-48662018000100009</article-id>
<article-id pub-id-type="doi">10.24245/mim.v34i1.1922</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Síndrome de Guillain-Barré: viejos y nuevos conceptos]]></article-title>
<article-title xml:lang="en"><![CDATA[Guillain-Barre syndrome: older and news concepts]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rebolledo-García]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Vargas]]></surname>
<given-names><![CDATA[PO]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Salgado-Calderón]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital General Dr. Nicolás San Juan  ]]></institution>
<addr-line><![CDATA[Toluca Estado de México]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro Médico Adolfo Lopez Mateos  ]]></institution>
<addr-line><![CDATA[Toluca Estado de México]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,IMSS Unidad de Medicina Familiar 222 ]]></institution>
<addr-line><![CDATA[Toluca Estado de México]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2018</year>
</pub-date>
<volume>34</volume>
<numero>1</numero>
<fpage>72</fpage>
<lpage>81</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0186-48662018000100009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0186-48662018000100009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0186-48662018000100009&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: En la actualidad el síndrome de Guillain-Barré (SGB) es la causa más frecuente de parálisis flácida aguda. La forma clásica de síndrome no ha sufrido modificaciones importantes en su comportamiento clínico; sin embargo, el espectro de variantes clínicas del síndrome es extenso, sustentado en los avances de la biología molecular y la inmunología que han permitido caracterizar mejor estas formas del síndrome de Guillain-Barré. Los anticuerpos anti-gangliósidos han reestructurado los criterios porque aumentan la sensibilidad y la especificidad del diagnóstico; debido a ello, los criterios clásicos son insuficientes para lograr una adecuada clasificación y discriminar los imitadores del síndrome. La evolución de los criterios debe cambiar la perspectiva en el abordaje del cuadro y normar la conducta terapéutica, sin sobrepasar el juicio clínico de la práctica médica diaria.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: Currently, Guillain-Barre syndrome (GBS) is the most frequent cause of acute flaccid paralysis. The classical form of syndrome has not undergone major changes in their clinical behavior; however, the spectrum of clinical variants of the syndrome is extensive, supporting advances in molecular biology and immunology have allowed better characterize these forms of GBS. The anti-ganglioside antibodies have restructured the criteria because they increase the sensitivity and specificity of diagnosis; because of this, the traditional criteria are inadequate for appropriated classification and discriminate imitators of the syndrome. The evolution of the criteria should change the perspective in addressing the box and regulate the therapeutic approach, without exceeding the clinical trial of daily medical practice.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Guillain-Barré]]></kwd>
<kwd lng="es"><![CDATA[anticuerpos]]></kwd>
<kwd lng="en"><![CDATA[Guillain-Barre syndrome]]></kwd>
<kwd lng="en"><![CDATA[Antibodies]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Clifford]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<source><![CDATA[History of British Neurology]]></source>
<year>2012</year>
<edition>1</edition>
<publisher-name><![CDATA[Imperial College Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>Guillain Barré &amp; Associated Inflammatory Neuropathies</collab>
<source><![CDATA[]]></source>
<year>2010</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Doorn]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Ruts]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome]]></article-title>
<source><![CDATA[Lancet Neurol]]></source>
<year>2008</year>
<volume>7</volume>
<page-range>939-50</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García Ramos]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
<name>
<surname><![CDATA[Cacho Díaz]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome de Guillain-Barré (SGB). Diagnóstico diferencial]]></article-title>
<source><![CDATA[Rev Mex Neuroci]]></source>
<year>2005</year>
<volume>6</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>448-54</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McGrogan A]]></surname>
<given-names><![CDATA[Gemma C]]></given-names>
</name>
<name>
<surname><![CDATA[MHelen Seaman]]></surname>
<given-names><![CDATA[ME.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The epidemiology of Guillain-Barré syndrome worldwide]]></article-title>
<source><![CDATA[Neuroepidemiology]]></source>
<year>2009</year>
<volume>32</volume>
<page-range>150-63</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[James]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sejvar]]></surname>
<given-names><![CDATA[ALS]]></given-names>
</name>
<name>
<surname><![CDATA[Matthew]]></surname>
<given-names><![CDATA[WB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Population incidence of Guillain-Barré syndrome: A systematic review and meta-analysis]]></article-title>
<source><![CDATA[Neuroepidemiology]]></source>
<year>2011</year>
<volume>36</volume>
<page-range>123-33</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yuki]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Hartung]]></surname>
<given-names><![CDATA[HP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guillain-Barré syndrome]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2012</year>
<volume>366</volume>
<page-range>2294-304</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Griffin]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[TW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guillain-Barré syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases]]></article-title>
<source><![CDATA[Brain]]></source>
<year>1995</year>
<volume>118</volume>
<page-range>577-95</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rees]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Soudain]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Campylobacter jejuni infection and Guillain-Barré syndrome]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1995</year>
<volume>333</volume>
<page-range>1374-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ropper]]></surname>
<given-names><![CDATA[AH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Guillain-Barré syndrome]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1992</year>
<volume>326</volume>
<page-range>1130-6</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lunn]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hughes]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The relationship between Cytomegalovirus infection and Guillain-Barré syndrome]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2011</year>
<volume>52</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>845-7</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Domínguez-Moreno]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Tolosa-Tort]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Patiño-Tamez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Quintero-Bauman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mortalidad asociada al diagnóstico de síndrome de Guillain-Barré en adultos ingresados en instituciones del sistema sanitario mexicano]]></article-title>
<source><![CDATA[Rev Neurol]]></source>
<year>2014</year>
<volume>58</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>4-10</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Tsai]]></surname>
<given-names><![CDATA[YT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Structures, biosynthesis, and functions of gangliosides-An overview]]></article-title>
<source><![CDATA[J Oleo Sci]]></source>
<year>2011</year>
<volume>60</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>537-44</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yuki]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guillain-Barré syndrome and anti-ganglioside antibodies: a clinician-scientist&#8217;s journey]]></article-title>
<source><![CDATA[Proc Jpn Acad Ser B Phys Biol Sci]]></source>
<year>2012</year>
<volume>88</volume>
<page-range>299-326</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wim]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
<name>
<surname><![CDATA[Laman]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Guillain-Barre&#8217; syndrome: a true case of molecular mimicry]]></article-title>
<source><![CDATA[Trends in Immunol]]></source>
<year>2004</year>
<volume>25</volume>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Osler]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
<name>
<surname><![CDATA[Sidell]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Guillain-Barré syndrome-The need for exact diagnostic criteria]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1960</year>
<volume>262</volume>
<page-range>964-9</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Asbury]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Cornblath]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of current diagnostic criteria for Guillain-Barré syndrome]]></article-title>
<source><![CDATA[Ann Neurol]]></source>
<year>1990</year>
<volume>27</volume>
<numero>^s21</numero>
<issue>^s21</issue>
<supplement>21</supplement>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fokke]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Van den Berg]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria]]></article-title>
<source><![CDATA[Brain]]></source>
<year>2014</year>
<volume>33</volume>
<numero>137</numero>
<issue>137</issue>
<page-range>33-43</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wakerley]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
<name>
<surname><![CDATA[Uncini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Yuki]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guillain-Barré and Miller Fisher syndromes-new diagnostic classification]]></article-title>
<source><![CDATA[Nat Rev Neurol]]></source>
<year>2014</year>
<volume>10</volume>
<page-range>537-44</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hughes]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Swan]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[van Doorn]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravenous immunoglobulin for Guillain-Barré syndrome]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2010</year>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vucic]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kiernan]]></surname>
<given-names><![CDATA[MC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guillain-Barre syndrome: An update]]></article-title>
<source><![CDATA[J Clin Neurosci]]></source>
<year>2009</year>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yuki]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relation between critical illness polyneuropathy and axonal Guillain-Barré syndrome]]></article-title>
<source><![CDATA[J Neurol Neurosurg Psychiatry]]></source>
<year>1999</year>
<volume>67</volume>
<page-range>121-33</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walgaard]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lingsma]]></surname>
<given-names><![CDATA[HF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early recognition of poor prognosis in Guillain-Barré syndrome]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2011</year>
<volume>76</volume>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[van Koningsveld]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Steyerberg]]></surname>
<given-names><![CDATA[EW]]></given-names>
</name>
<name>
<surname><![CDATA[Hughes]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A clinical prognostic scoring system for Guillain-Barré syndrome]]></article-title>
<source><![CDATA[Lancet Neurol]]></source>
<year>2007</year>
<volume>6</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>589-94</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hughes]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Cornblath]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guillain-Barré syndrome]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2005</year>
<volume>366</volume>
<page-range>1653-66</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wöhrle]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Spengos]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alcohol-related acute axonal polyneuropathy: A differential diagnosis of Guillain-Barré syndrome]]></article-title>
<source><![CDATA[Arch Neurol]]></source>
<year>1998</year>
<volume>55</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1329-34</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martens-Le Bouar]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Korinthenberg]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Polyradiculoneuritis with myelitis: a rare differential diagnosis of Guillain-Barre syndrome]]></article-title>
<source><![CDATA[Neuropediatrics]]></source>
<year>2002</year>
<volume>33</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>93-6</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruts]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Drenthen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
<name>
<surname><![CDATA[van Doorn]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dutch GBS Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2010</year>
<volume>74</volume>
<numero>21</numero>
<issue>21</issue>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hughes]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Wijdicks]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Supportive care for patients with Guillain-Barré syndrome]]></article-title>
<source><![CDATA[Arch Neurol]]></source>
<year>2005</year>
<volume>62</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1194-8</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hughes]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Wijdicks]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Practice parameter: Immunotherapy for Guillain-Barré syndrome]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2003</year>
<volume>61</volume>
<page-range>736-40</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Willison]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
<name>
<surname><![CDATA[Doorn]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guillain-Barré syndrome]]></article-title>
<source><![CDATA[Lancet Seminar]]></source>
<year>2016</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
